The cancer drug Revlimid is Celgene’s (CELG) bread and butter, accounting for two-thirds of its product sales. But some of its other drugs are showing higher growth rates than its flagship product. Last year, Revlimid sales rose 16% from 2013. By comparison, sales of Abraxane — a treatment for breast, lung and pancreatic cancer — climbed 31% last year.